---
figid: PMC5352107__oncotarget-08-1913-g004
figlink: /pmc/articles/PMC5352107/figure/F4/
number: Figure 4
caption: Microtubule stabilizers polymerize tubulin in the microtubule, thereby inhibiting
  cell division. Anthracyclines inhibit RNA synthesis by intercalating between base
  pairs of the DNA/RNA strand, thus preventing the replication of rapidly growing
  cancer cells. Platinums generate intra- and inter-strand double-stranded DNA crosslinks,
  preventing the formation of the replication fork and inhibiting cell division. PARP
  inhibitors prevent the repair of single-strand breaks that occur during cell cycle
  especially in BRCA-mutated cells. Angiogenesis inhibitors block the growth of new
  blood vessels by inhibiting VEGF. EGFR inhibitors bind to EGFR and turn off the
  uncontrolled growth of cancer cells with EGFR mutations. TK inhibitors block tumor
  growth through inhibiting intracellular tyrosine kinase activity. mTOR inhibitors
  suppress cancer cell growth and proliferation through targeting the PI3K/Akt/mTOR
  signaling pathway. Statins inhibit the conversion of HMG-CoA to mevalonate in the
  cholesterol biosynthesis pathway. The anti-cancer effects of statins may involve
  the inhibition of multiple signaling pathways important for the malignant phenotype
  of cancer cells. EGFR, epidermal growth factor receptor; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme
  A; mTOR, mammalian target of rapamycin; PARP, poly(ADP-ribose) polymerase; TK, tyrosine
  kinase.
pmcid: PMC5352107
papertitle: 'Triple-negative breast cancer: is there a treatment on the horizon?.'
reftext: Hui Yao, et al. Oncotarget. 2017 Jan 3;8(1):1913-1924.
pmc_ranked_result_index: '5373'
pathway_score: 0.8250722
filename: oncotarget-08-1913-g004.jpg
figtitle: 'Triple-negative breast cancer: is there a treatment on the horizon?'
year: '2017'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5352107__oncotarget-08-1913-g004.html
  '@type': Dataset
  description: Microtubule stabilizers polymerize tubulin in the microtubule, thereby
    inhibiting cell division. Anthracyclines inhibit RNA synthesis by intercalating
    between base pairs of the DNA/RNA strand, thus preventing the replication of rapidly
    growing cancer cells. Platinums generate intra- and inter-strand double-stranded
    DNA crosslinks, preventing the formation of the replication fork and inhibiting
    cell division. PARP inhibitors prevent the repair of single-strand breaks that
    occur during cell cycle especially in BRCA-mutated cells. Angiogenesis inhibitors
    block the growth of new blood vessels by inhibiting VEGF. EGFR inhibitors bind
    to EGFR and turn off the uncontrolled growth of cancer cells with EGFR mutations.
    TK inhibitors block tumor growth through inhibiting intracellular tyrosine kinase
    activity. mTOR inhibitors suppress cancer cell growth and proliferation through
    targeting the PI3K/Akt/mTOR signaling pathway. Statins inhibit the conversion
    of HMG-CoA to mevalonate in the cholesterol biosynthesis pathway. The anti-cancer
    effects of statins may involve the inhibition of multiple signaling pathways important
    for the malignant phenotype of cancer cells. EGFR, epidermal growth factor receptor;
    HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; mTOR, mammalian target of rapamycin;
    PARP, poly(ADP-ribose) polymerase; TK, tyrosine kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PARP15
  - PARP3
  - TNKS
  - TIPARP
  - PARP10
  - PARP16
  - PARP1
  - PARP2
  - PARP14
  - PARP9
  - VEGFA
  - PARP4
  - MTOR
  - TNKS2
  - EGFR
  - VEGFD
  - PGF
  - PARP6
  - PARP11
  - PARP12
  - VEGFB
  - PARP8
  - ACSL4
  - VEGFC
  - Taxanes
  - Ixabepilone
  - Pazopanib
  - Cisplatin
  - Doxorubicin
  - Lovastatin
  - Mevalonate
  - Epirubicin
  - Anthracyclines
  - Simvastatin
genes:
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP15
  entrez: '165631'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP3
  entrez: '10039'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TNKS
  entrez: '8658'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TIPARP
  entrez: '25976'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP10
  entrez: '84875'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP16
  entrez: '54956'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP1
  entrez: '142'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP2
  entrez: '10038'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP14
  entrez: '54625'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP9
  entrez: '83666'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP4
  entrez: '143'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TNKS2
  entrez: '80351'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP6
  entrez: '56965'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP11
  entrez: '57097'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP12
  entrez: '64761'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP8
  entrez: '79668'
- word: ACSL4
  symbol: ACSL4
  source: hgnc_symbol
  hgnc_symbol: ACSL4
  entrez: '2182'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
chemicals:
- word: Taxanes
  source: MESH
  identifier: C080625
- word: Ixabepilone
  source: MESH
  identifier: C430592
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Cisplatin
  source: MESH
  identifier: D002945
- word: Doxorubicin
  source: MESH
  identifier: D004317
- word: Lovastatin
  source: MESH
  identifier: D008148
- word: Mevalonate
  source: MESH
  identifier: D008798
- word: Epirubicin
  source: MESH
  identifier: D015251
- word: Anthracyclines
  source: MESH
  identifier: D018943
- word: Simvastatin
  source: MESH
  identifier: D019821
diseases: []
---
